PVI
ANIP icon

Pura Vida Investments’s ANI Pharmaceuticals ANIP Stock Holding History

Pura Vida Investments’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-28,875
Closed -$1.43M – 71
2017
Q1 		$1.43M Buy
28,875
+2,625
+10% +$147K 0.42% 59
2016
Q4 		$1.59M Buy
+26,250
New +$1.61M 0.58% 46

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Pura Vida Investments's ANIP Position: Q2 2017 in Review

Pura Vida Investments sold out of ANI Pharmaceuticals (ANIP) in Q2 2017, closing a stake of 28,875 shares — an estimated $1.43M sold.

Pura Vida Investments first reported a position in ANIP in Q4 2016 and held it in 2 quarters. The position peaked at $1.59M in Q4 2016. 151 funds tracked by Wall St. Rank hold ANIP as of Q2 2017.

  • Pura Vida Investments reported no remaining ANI Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Pura Vida Investments sold 28,875 ANI Pharmaceuticals shares in Q2 2017, an estimated $1.43M.
  • Pura Vida Investments first reported a position in ANI Pharmaceuticals in Q4 2016 and held it in 2 quarters.
  • Pura Vida Investments's ANI Pharmaceuticals position peaked at $1.59M in Q4 2016.
  • 151 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2017.

Based on Pura Vida Investments's 13F filing for Q2 2017, filed 14 Aug 2017.